Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 223

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Ackerman, Allison, Klein, Oliver, McDermott, David F., Wang, Wei, Ibrahim, Nageatte, Lawrence, Donald P., Gunturi, Anasuya, Flaherty, Keith T., Hodi, F. Stephen, Kefford, Richard, Menzies, Alexander M., Atkins, Michael B., Long, Georgina V., Sullivan, Ryan J.·2014·Cancer
DOI 10.1002/cncr.28620
Open this paper in CoChat — free account

Abstract

BACKGROUND: The immunotherapy (IT) agents ipilimumab and interleukin‐2 as well as BRAF inhibitors (BRAFi) vemurafenib and dabrafenib, with or without trametinib (MEK inhibitors), are all FDA‐approved treatments for BRAF metastatic melanoma, but there are few studies to guide optimal sequencing. This retrospective analysis describes the outcomes of patients treated with either BRAFi before IT or IT before BRAFi. METHODS: A cohort of patients treated with BRAFi alone or with MEK inhibitor was retrospectively identified. Response rate (RR), overall survival (OS), and progression‐free survival (PFS) were evaluated for the entire cohort, subdivided by BRAFi prior to or after IT. RESULTS: RR and median PFS and OS calculated from commencement of BRAFi following IT (N = 32) were 57%, 6.7 months (95% confidence interval [CI] = 4.3‐9.1 months), and 19.6 months (95% CI = 10.0‐undefined months), respectively; whereas for BRAFi initially (N = 242) were 66%, 5.6 months (95% CI = 4.7‐6.8 months), and 13.4 months (95% CI = 10.1‐17.0 months). Results were similar when controlled for prognostic variables. A total of 193 patients discontinued BRAFi, with OS of 2.9 months (range of 1.8‐4.4 months) from day of BRAFi discontinuation. Forty patients subsequently received IT with ipilimumab. Only half could complete 4 doses of ipilimumab; PFS with ipilimumab was 2.7 months (95% CI = 1.8‐3.1 months) and OS was 5.0 months (95% CI = 3.0‐8.8 months). CONCLUSIONS: In this retrospective analysis, prior treatment with IT does not appear to negatively influence response to BRAFi. Outcomes for IT with ipilimumab following BRAFi discontinuation are poor. Randomized controlled trials are needed to define if sequencing IT prior to BRAFi therapy is superior to sequencing BRAFi prior to IT. Cancer 2014;120:1695–1701. © 2014 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28620

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 223

Metadata

Authors
Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R., Menzies, A. M., Atkins, M. B., Long, G. V., & Sullivan, R. J.
Venue
Cancer
Publisher
Wiley
Published
2014-02-27
Volume
120
Issue
11
Pages
1695-1701
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
DOI
10.1002/cncr.28620
OpenAlex
W1557490668
Cited by
223
References
7
FWCI
13.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. https://app.cochat.ai/papers/10.1002/cncr.28620
The paper
Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R., Menzies, A. M., Atkins, M. B., Long, G. V., & Sullivan, R. J. (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. https://doi.org/10.1002/cncr.28620

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.